Tag Archives: Myriad

Life Science Patenting to Iancu – “We need help too!”

In his remarks presented at the recent 10th Annual Patent Law & Policy Conference at Georgetown University Law School, USPTO Director Andrei Iancu outlined the analytical framework for the new, eagerly awaited, PTO Guidance on patent eligible subject matter. Although … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , | Leave a comment

Roche Molecular Systems, Inc. v. Cepheid – Are Primers “Natural Products”?

Anyone familiar with the fate of claims to primers used in PCR, to amplify a stretch of target DNA in order to determine whether or not a significant mutation is present, could write the opinion in this appeal (No. 2017-1690 … Continue reading

Posted in Section 101 | Tagged , , , , , , , , , , | 1 Comment

Ex parte Parenteau – PTAB Skips Step One of the Mayo/Alice Test?

In ex parte Ho, the subject of my last post, the PTAB reversed the Examiner’s rejection of claims to a population of bone marrow cells obtained by two-stage culturing that expressed or failed to express certain markers. The PTAB wrote … Continue reading

Posted in Section 101, Section 103 | Tagged , , , , , , , , | Leave a comment

Bhagat v. Iancu – Did the Myriad Decision Overrule Funk Bros.?

A September 6th post by Dennis Crouch at PatentlyO (“A Mixture of Known Compounds is Unpatentable without a Transformation“) led me to a closer reading of the cert. petition filed in Bhagat v. Iancu, (Case No. 18-277) an appeal from … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , , | Leave a comment